RCKT
NASDAQ · Biotechnology
Rocket Pharmaceuticals Inc
$4.14
-0.25 (-5.69%)
Open$4.38
Previous Close$4.39
Day High$4.60
Day Low$4.13
52W High$9.35
52W Low$2.19
Volume—
Avg Volume3.59M
Market Cap503.76M
P/E Ratio—
EPS$-2.01
SectorBiotechnology
Analyst Ratings
Buy
21 analysts
Price Target
+307.5% upside
Current
$4.14
$4.14
Target
$16.87
$16.87
$13.87
$16.87 avg
$23.44
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 67.67M | 66.73M | 71.52M |
| Net Income | -17,020,193 | -15,934,880 | -16,470,876 |
| Profit Margin | -25.2% | -23.9% | -23.0% |
| EBITDA | -23,292,743 | -22,716,839 | -22,207,941 |
| Free Cash Flow | -11,691,320 | -15,075,459 | -16,131,538 |
| Rev Growth | +1.5% | +16.6% | +10.7% |
| Debt/Equity | 1.36 | 1.21 | 1.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |